Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Evaluation of the Effect of Different Mesenchymal Stem Cell Microvesicles on Diabetic Wound Healing.

Kemaloğlu CA., Taşkın Ö., Gönen ZB., Yay AH., Bozkurt F.

Randomized Controlled Trial with a reported sample of 10 on Diabetic Foot, Chronic Wound, published in J Clin Pract Res (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
J Clin Pract Res (2026)
Country
Turkey
Reported sample size
10
Source database
PubMed
PMID
41908353
PMCID
PMC13022841
DOI
10.14744/cpr.2026.58278

Abstract (original English)

Objective Mesenchymal stem cell (MSC)-derived microvesicles play a pivotal role in the regenerative cascade of wound healing. This study aimed to comparatively evaluate the therapeutic potential of microvesicles isolated from different MSC sources in the healing of diabetic cutaneous wounds. Materials and methods Forty Wistar albino rats were randomly assigned to four experimental groups (n=10 per group). Following the induction of diabetes and the creation of full-thickness circular dorsal skin defects, each group received a distinct treatment: Group 1 received saline (control), Group 2 received adipose-derived stem cell microvesicles (ADSC-MVs), Group 3 received umbilical cord-derived stem cell microvesicles (UCDSC-MVs), and Group 4 received bone marrow-derived stem cell microvesicles (BMDSC-MVs). Outcomes related to re-epithelialization, neovascularization, and collagen matrix formation were evaluated both macroscopically and histologically. Results The microvesicle-treated groups demonstrated faster wound closure and improved collagen fiber alignment compared with the control group. Angiogenic activity was increased in all treatment groups, with the most pronounced effects observed in the UCDSC-MVs group. Notably, the UCDSC-MVs group exhibited a significantly greater epithelial tongue length than the control group on postoperative days 3 and 14 (p=0.008 and p Conclusion The

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research